Mustang Bio Inc (NAS:MBIO)
$ 0.2185 0.004 (1.85%) Market Cap: 8.13 Mil Enterprise Value: 4.86 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

Mustang Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 01:30PM GMT
Release Date Price: $9.47 (+0.98%)
Arthur He
H.C. Wainwright & Co., LLC - Biotech Equity Research Analyst

Good morning, everyone. And thank you for joining H.C. Wainwright 24th Annual Global Investment Conference. My name is Arthur He, and I'm a biotech equity research analyst at H.C. Wainwright.

Please welcome, our next presenter, Dr. Manny Litchman, the CEO and the President of Mustang Bio. Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for cancers and genetic disease. Manny, the floor is yours.

Manny Litchman
Mustang Bio, Inc. - President, CEO & Director

Thanks very much, Arthur. And thanks, everybody, for your interest in Mustang Bio. So Mustang Bio was pioneering innovative CAR-T therapies for cancer, as well as gene therapies for primary immunodeficiencies.

Our key assets are our people. We have about 110 or so people on University of Massachusetts Medical School campus in that state-of-the-art manufacturing facility that you see at the right. And our lead programs, are MB-106, a first-in-class CD20

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot